In Shou et al., HR values for the association of increased ADAM17 expression with poor OS were lower (HR = 2.067, 95% CI = 1.475–2.883, p = 0.000); however, high levels of significance of the relationship between expression and other clinical parameters of poor prognosis were observed: tumor size (p = 0.000), depth of invasion (p = 0.000), TNM stage (p = 0.000), lymph node metastasis (p = 0.000) and distant metastasis (p = 0.000) [184]. This evidence concerns the gene ADAM17 and metastatic malignant neoplasm in the lymph nodes.